- Home
- MGRX vs CMMB Comparison
MGRX vs CMMB Comparison
Compare MGRX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- CMMB
- Stock Information
- Founded
- MGRX 2021
- CMMB 2004
- Country
- MGRX United States
- CMMB Israel
- Employees
- MGRX N/A
- CMMB N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- CMMB Health Care
- Exchange
- MGRX Nasdaq
- CMMB Nasdaq
- Market Cap
- MGRX 18.6M
- CMMB 22.0M
- IPO Year
- MGRX 2023
- CMMB N/A
- Fundamental
- Price
- MGRX $1.71
- CMMB $1.03
- Analyst Decision
- MGRX
- CMMB Strong Buy
- Analyst Count
- MGRX 0
- CMMB 2
- Target Price
- MGRX N/A
- CMMB $8.50
- AVG Volume (30 Days)
- MGRX 145.9K
- CMMB 134.4K
- Earning Date
- MGRX 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- MGRX N/A
- CMMB N/A
- EPS Growth
- MGRX N/A
- CMMB N/A
- EPS
- MGRX N/A
- CMMB N/A
- Revenue
- MGRX $511,084.00
- CMMB N/A
- Revenue This Year
- MGRX N/A
- CMMB N/A
- Revenue Next Year
- MGRX N/A
- CMMB N/A
- P/E Ratio
- MGRX N/A
- CMMB N/A
- Revenue Growth
- MGRX N/A
- CMMB N/A
- 52 Week Low
- MGRX $1.32
- CMMB $0.87
- 52 Week High
- MGRX $7.66
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- MGRX 51.65
- CMMB 22.04
- Support Level
- MGRX $1.61
- CMMB $1.07
- Resistance Level
- MGRX $1.77
- CMMB $1.14
- Average True Range (ATR)
- MGRX 0.14
- CMMB 0.06
- MACD
- MGRX 0.02
- CMMB -0.00
- Stochastic Oscillator
- MGRX 43.68
- CMMB 2.63
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.